Seiichiro Hojo

Dose Finding of Lenvatinib in Subjects With Advanced Hepatocellular Carcinoma Based on Population Pharmacokinetic and Exposure-Response Analyses

Toshiyuki Tamai, Seiichi Hayato, Seiichiro Hojo et al. · The Journal of Clinical Pharmacology · 2017 · 102 citations · Full text

Pharmacy, Oncology, Pharmacology +16

Safety and efficacy of topical E6005, a phosphodiesterase 4 inhibitor, in <scp>J</scp> apanese adult patients with atopic dermatitis: Results of a randomized, vehicle‐controlled, multicenter clinical trial

Masutaka Furue, Yasumi Kitahara, Hideto Akama et al. · The Journal of Dermatology · 2014 · 75 citations

Medicine, Dermatology, Pharmacology +13

Safety, pharmacokinetics, and efficacy of E6011, an antifractalkine monoclonal antibody, in a first-in-patient phase 1/2 study on rheumatoid arthritis

Yoshiya Tanaka, Tsutomu Takeuchi, Hisanori Umehara et al. · Modern Rheumatology · 2017 · 59 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Phase II study of tazemetostat for relapsed or refractory B‐cell non‐Hodgkin lymphoma with <i>EZH2</i> mutation in Japan

Koji Izutsu, Kiyoshi Ando, Momoko Nishikori et al. · Cancer Science · 2021 · 58 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Effect of topical phosphodiesterase 4 inhibitor E6005 on Japanese children with atopic dermatitis: Results from a randomized, vehicle‐controlled exploratory trial

Osamu Nemoto, Nobukazu Hayashi, Yasumi Kitahara et al. · The Journal of Dermatology · 2015 · 43 citations

Medicine, Dermatology, Pharmacology +13